The autonomous organization DMC (Data Monitoring Committee) has advised in October that the part 3 experiment of Gilead Sciences, Inc. (NASDAQ:GILD) new cancer drug idelalisib be reduced as there is clear proof that it was helping patients. Studies carried out have proved that patients who are receiving idelalisib along with another drug, Rituxan (manufactured by Roche), lived more and their cancer did not increase. Gileads drug has already been presented to the FDA for sanction to be used as a a treatment for NHL (non-Hodgkin’s lymphoma. The company is now thinking of asking the FDA to sanction the drug for treatment of CLL (chronic lymphocytic leukemia). Gilead aims to be a competitor in the area of cancer and the launch of this drug next year will help it achieve that aim.
Though the new drug when it enters the market will be in direct competition with ibrutinib a medicine that has received a lot of publicity for its known capacity to treat leukemia created jointly by Pharmacyclics (PCYC) and Johnson & Johnson (JNJ). This medicine is due to be launched in 2014.
The DMC advice to reduce the experiment time of the medicine was based on a study that showed excellent statistical efficiency and longer living for patients suffering from cancer and being treated with idelalisib and Rituxan. Behind this advise of the DMC which is done in very few cases, it is not right for patients to be treated with a drug which is not up to the mark and now all patients would be able to receive the new drug once it hits the market.
Idelalisib was being created to treat cancer alone or in combination with other drugs. At the moment three other drugs which are with Arzerra from Glaxo (GSK) and Genmab with Rituxan, , and a combination of Rituxan and Treanda (from Teva (TEVA).
